Roche Gets CE Mark for Elecsys NfL MS Blood Test
BASEL, Switzerland, April 13, 2026 Roche has announced that its Elecsys® Neurofilament Light Chain (NfL) blood test has received...
Neuroinflammation
Advertisement
Tiziana Life Sciences Nasal Therapy Boosts Brain Health
Boston, MA, USA – April 1, 2026 In a promising development for age-related cognitive decline and neurodegenerative disorders, Tiziana...
Jupiter Neurosciences Aligns Capital With Clinical Growth
JUPITER, Fla., Feb. 23, 2026 — Jupiter Neurosciences, a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system...
Jupiter Expands Nugevia™ Strategy for GLP-1 Users
Jupiter, Florida | January 28, 2026 — Jupiter Neurosciences, Inc., a clinical-stage pharmaceutical company, announced a strategic expansion of...
New Alzheimer’s Mechanism Links APP and Hv1 Channels in Brain Inflammation
Irvine, Calif. – October 23, 2025 Researchers at the University of California, Irvine have uncovered a previously unrecognised molecular...
Advertisements
FDA Grants Orphan Drug Status to Cellenkos’ CK0803 for ALS Treatment
HOUSTON, Oct. 20, 2025 – The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to...
Alzheimer’s and Eye Drug Updates Highlight InMed FY2025
Vancouver, BC, September 23, 2025 – InMed Pharmaceuticals has reported its full‐year fiscal 2025 financial results and provided a...
Wheeler Bio and MindImmune Partner on Alzheimer’s Therapy MITI-101
OKLAHOMA CITY, Sept. 17, 2025 – Wheeler Bio, Inc., a U.S.-based contract development and manufacturing organization (CDMO), announced today...
Coya’s COYA 303 Shows Promise in Neuroinflammation and Treg Boost
HOUSTON, Sept. 16, 2025 – Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company specializing in regulatory T cell...
Advertisement
